Mandate

Vinge represents Symrise in connection with its mandatory offer on Probi

February 06, 2014

Symrise AG has, after having acquired shares corresponding to approximately 30.03 per cent of the votes in Probi AB (publ), launched a mandatory offer to the shareholders in Probi, with an offered price of SEK 40.10 per share. Vinge represents Symrise in connection with the mandatory offer.

Symrise is a global supplier of fragrances, flavourings, cosmetic, active ingredients, and raw materials as well as functional ingredients. The company’s share is listed on the Frankfurt Stock Exchange and the market capitalisation of Symrise is EUR 4 billion.

Probi is a research-driven biotechnology company focused on the global probiotics market. Through Probi’s research Probi has developed probiotics with well-documented beneficial health effects. The company’s share is listed on NASDAQ OMX Stockholm, Small cap and the market capitalisation of Probi is approximately MSEK 375.

Vinge’s team primarily consists of Jesper Schönbeck, Oskar Belani, Joakim Hagberg and Sabina Börjesson.

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025